SGT-212

Phase 1Small molecule

SSolid Biosciences Inc.

SGT-212 is one of 2 small molecule programs targeting Friedreich's Ataxia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Friedreich's AtaxiaRecruiting

Friedreich's AtaxiaPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Friedreich's Ataxia

#DrugCompanyPhaseTrials

Vatiquinone

PPTC Therapeutics

Phase 3

1 2

SGT-212

SSolid Biosciences Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 1Recruiting

Friedreich's Ataxia

NCT07180355

Clinical

Trials by Indication[1]

Friedreich's Ataxia1 trial

A Phase 1b First-in-Human, Open-Label, Dose-Finding Trial to Evaluate the Safety and Tolerability of SGT-212 Delivered Via Dual Intradentate Nucleus (IDN) and Intravenous (IV) Administration to Participants With Friedreich's Ataxia (FA)

Recruiting·SSolid Biosciences Inc.·Phase 1·NCT07180355·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SGT-212. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SGT-212 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SGT-212. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Solid Biosciences Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSolid Biosciences Inc.

SGT-212

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Friedreich's Ataxia1 trial

References

Drug Info

Quick Facts

Related News